Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nile Therapeutics has entered into a worldwide, exclusive license agreement with Mayo Clinic for the rights to commercially develop CU-NP, a rationally designed natriuretic peptide.
Subscribe to our email newsletter
Pursuant to the terms of the license agreement, Nile will pay development milestones and royalties based on sales of the licensed product.
CU-NP was designed by researchers at Mayo to combine the favorable hemodynamic venodilating effects of C-type natriuretic peptide (CNP) generated via NPR-B receptor agonism, with the beneficial renal effects of urodilatin generated via NPR-A receptor agonism.
CU-NP consists of amino acid chains identical to those produced by the human body, specifically the ring structure of C-type natriuretic peptide and the N- and C-termini of urodilatin.
Peter Strumph, CEO of Nile, said: “We are extremely excited to add CU-NP to our pipeline. With the two peptide assets, CD-NP and CU-NP, we believe Nile has the potential to develop best-in-class natriuretic peptides for multiple cardiovascular and renal indications.”